Pharmacology/Pharmaceutical Industry
RCT | Group support and skill-based learning reduce opioid use in chronic pain, but leads to no effect on pain perception
29 May, 2023 | 11:14h | UTCReducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
News Release: New treatment helps people stop addictive opioid painkillers used for chronic pain – University of Warwick
Six long-standing questions about antibiotic prophylaxis in surgery
29 May, 2023 | 10:59h | UTCSix Long-Standing Questions about Antibiotic Prophylaxis in Surgery – Antibiotics
Consensus Statement | Rationale and clinical application of antimicrobial stewardship principles in the intensive care unit
24 May, 2023 | 13:15h | UTC
RCT | Effectiveness of genotype-specific tricyclic antidepressant dosing in patients with major depressive disorder
23 May, 2023 | 12:52h | UTC
Commentary on Twitter
Genotype-guided tricyclic antidepressant dosing may help patients with depression reach faster therapeutic plasma concentrations, with potentially fewer adverse effects. https://t.co/06cIaQjmwV pic.twitter.com/ZBdXZLeWc3
— JAMA Network Open (@JAMANetworkOpen) May 8, 2023
Drug-induced abnormal involuntary movements: prevalence and treatment
22 May, 2023 | 13:30h | UTC
New pharmacological agents and novel cardiovascular pharmacotherapy strategies
22 May, 2023 | 13:24h | UTC
Commentary on Twitter
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022: a focused review by the ESC Working Group on #Pharmacotherapy ? https://t.co/DZ6FTqYwxk @jpkaski #HF #AFib #diabetes #lipids #EHJPharmacotherapy @AgewallStefan @FeliceGragnano pic.twitter.com/1DTCewbyPv
— European Society of Cardiology Journals (@ESC_Journals) May 20, 2023
M-A | Limited evidence for safety and effectiveness of most antidepressants in chronic pain management
18 May, 2023 | 13:50h | UTC
RCT | Once-weekly insulin icodec shows non-inferiority to daily insulin glargine in type 2 diabetes patients
18 May, 2023 | 13:48h | UTCSwitching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Review | Estimating risk of antidepressant withdrawal from a review of published data
9 May, 2023 | 14:39h | UTCEstimating Risk of Antidepressant Withdrawal from a Review of Published Data – CNS Drugs
Commentary: Researchers Identify Factors to Predict Risk of Antidepressant Withdrawal – Mad in America
2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults
8 May, 2023 | 13:25h | UTC
Review | Deprescribing considerations for older people in general practice
8 May, 2023 | 13:23h | UTCRelated:
RCT | A deprescribing intervention reduced medication burden among older adults in post-acute care
Deprescribing proton pump inhibitors – Australian Journal of General Practice
Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports
Deprescribing in Palliative Cancer Care – Life
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360
Polypharmacy Management in Older Patients – Mayo Clinic Proceedings
Eliminating Medication Overload: A National Action Plan – Lown Institute
Common ED Medication Errors: Polypharmacy – emDocs
Current and future perspectives on the management of polypharmacy – BMC Family Practice
Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international
Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety
Brief review | What’s new in therapeutic drug monitoring of antimicrobials?
8 May, 2023 | 13:08h | UTCWhat’s new in therapeutic drug monitoring of antimicrobials? – Intensive Care Medicine
Commentary on Twitter
TDM of antimicrobials in #ICU
?life-saving drugs, difficult pharmacology
?TDM: why do we need it?
?uncertainties
concentrations to be targeted/where
adjusting dose if out of range
steady state: prerequisite?
outcomes when studying TDM#FOAMcc
?️ https://t.co/0DiDW7ONvV pic.twitter.com/0SQH0DR7Z0— Intensive Care Medicine (@yourICM) May 3, 2023
M-A | Direct oral anticoagulants versus warfarin across the spectrum of kidney function in patients with AF
3 May, 2023 | 15:32h | UTCDirect Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF – Circulation (free for a limited period)
Commentary on Twitter
Direct Oral Anticoagulants versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses from COMBINE AF @jlharrington_md #AHAJournals https://t.co/6Rzlt09m9W pic.twitter.com/2oknvnken8
— Circulation (@CircAHA) April 18, 2023
RCT | An herbal-based injection reduced 28-day mortality in patients with sepsis
2 May, 2023 | 13:58h | UTC
Commentary on Twitter
Among patients with sepsis, treatment with Xuebijing injection, compared with the placebo group, resulted in lower 28-day mortality. https://t.co/tHwnq6mKu8
— JAMA Internal Medicine (@JAMAInternalMed) May 1, 2023
Syphilis in dermatology | Recognition and management
2 May, 2023 | 13:40h | UTCSyphilis in Dermatology: Recognition and Management – American Journal of Clinical Dermatology
Commentary on Twitter
Syphilis in Dermatology: Recognition and Management
This guide by Amor Khachemoune et al. discusses the current epidemiology of syphilis and focuses on practice aspects of diagnosis and management, including public health reporting.#Syphilishttps://t.co/uLsVaw4jXP pic.twitter.com/sbXhFCk5De— Kathy Fraser (@AmJClinDerma) January 23, 2023
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials
2 May, 2023 | 13:25h | UTC
M-A | Low-dose triple and quadruple antihypertensives outperform monotherapy in blood pressure reduction
28 Apr, 2023 | 13:23h | UTCEfficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis – JAMA Cardiology (free for a limited period)
Commentary: Low-Dose Polypills Top Other Approaches for Initial BP Control: Meta-analysis – TCTMD
Cohort Study | The association between antihypertensive treatment and serious adverse events by age and frailty
28 Apr, 2023 | 12:45h | UTC
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
24 Apr, 2023 | 13:40h | UTCImmediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)
See Tweet from one of the authors with infographic and link to free full text here
RCT | Piperacillin-tazobactam better than cefoxitin in antimicrobial prophylaxis for open pancreatoduodenectomy
21 Apr, 2023 | 13:08h | UTCPiperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Informing a Rational Approach to Antimicrobial Prophylaxis in Open Pancreatoduodenectomy – JAMA (free for a limited period)
Commentary on Twitter
Study findings support the use of piperacillin-tazobactam as perioperative antimicrobial prophylaxis for open pancreatoduodenectomy. https://t.co/M9qAVrePRH pic.twitter.com/xq01qPTHQO
— JAMA (@JAMA_current) April 20, 2023
M-A | Adverse events related to tirzepatide (a dual GIP/GLP-1 receptor agonist)
21 Apr, 2023 | 12:59h | UTCAdverse Events Related to Tirzepatide – Journal of the Endocrine Society
Related:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Study shows approximately half of infectious diseases guideline authors have conflicts of interest with pharmaceutical companies
18 Apr, 2023 | 13:28h | UTC
Consensus Paper | Strategies to prevent Clostridioides difficile infections in acute-care hospitals
17 Apr, 2023 | 13:17h | UTCCommentary: New guidance deems antibiotic stewardship essential for preventing C diff infections – CIDRAP
RCT | Heterogeneity in blood pressure response to 4 antihypertensive drugs
17 Apr, 2023 | 13:14h | UTCHeterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial – JAMA (free for a limited period)
News Release: Personalized blood pressure treatment more effective – Uppsala University
Phase 2 RCT | High-dose VE303 reduces recurrent Clostridioides difficile infection rates
17 Apr, 2023 | 13:12h | UTCVE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual Abstract
